ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Guided Therapeutics Inc (QB)

Guided Therapeutics Inc (QB) (GTHP)

0.14
0.015
(12.00%)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
0.14
Bid
0.0901
Ask
0.14
Volume
2,680
0.12 Day's Range 0.14
0.0644 52 Week Range 0.23
Market Cap
Previous Close
0.125
Open
0.12
Last Trade
180
@
0.14
Last Trade Time
Financial Volume
$ 348
VWAP
0.129954
Average Volume (3m)
13,945
Shares Outstanding
77,967,594
Dividend Yield
-
PE Ratio
-2.99
Earnings Per Share (EPS)
-0.05
Revenue
98k
Net Profit
-3.66M

About Guided Therapeutics Inc (QB)

Guided Therapeutics, Inc. is the developer of the LuViva Advanced Cervical Scan, a rapid and painless test for the early detection of disease that leads to cervical cancer. LuViva is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tes... Guided Therapeutics, Inc. is the developer of the LuViva Advanced Cervical Scan, a rapid and painless test for the early detection of disease that leads to cervical cancer. LuViva is designed to quickly eliminate false positive Pap and HPV results and discover cervical disease missed by existing tests. LuViva works by shining light on the cervical and reading the returned light with a spectrometer. LuViva looks for chemical and physical markers of precancer. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are known immediately. For more information, visit www.guidedinc.com. Show more

Sector
Electromedical Apparatus
Industry
Electromedical Apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
Guided Therapeutics Inc (QB) is listed in the Electromedical Apparatus sector of the OTCMarkets with ticker GTHP. The last closing price for Guided Therapeutics (QB) was $0.13. Over the last year, Guided Therapeutics (QB) shares have traded in a share price range of $ 0.0644 to $ 0.23.

Guided Therapeutics (QB) currently has 77,967,594 shares outstanding. The market capitalization of Guided Therapeutics (QB) is $9.75 million. Guided Therapeutics (QB) has a price to earnings ratio (PE ratio) of -2.99.

GTHP Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.04400.10.140.086178850.125CS
40.0312528.73563218390.108750.140.086195170.10503321CS
120.03533.33333333330.1050.140.0644139450.09612485CS
26-0.021-13.04347826090.1610.1990.0644137920.12046494CS
520.0555.55555555560.090.230.0644144460.12719662CS
156-0.37895-73.02244917620.518950.60.062183850.20151376CS
260-0.315-69.23076923080.45510.062160160.31344538CS

GTHP - Frequently Asked Questions (FAQ)

What is the current Guided Therapeutics (QB) share price?
The current share price of Guided Therapeutics (QB) is $ 0.14
How many Guided Therapeutics (QB) shares are in issue?
Guided Therapeutics (QB) has 77,967,594 shares in issue
What is the market cap of Guided Therapeutics (QB)?
The market capitalisation of Guided Therapeutics (QB) is USD 9.75M
What is the 1 year trading range for Guided Therapeutics (QB) share price?
Guided Therapeutics (QB) has traded in the range of $ 0.0644 to $ 0.23 during the past year
What is the PE ratio of Guided Therapeutics (QB)?
The price to earnings ratio of Guided Therapeutics (QB) is -2.99
What is the cash to sales ratio of Guided Therapeutics (QB)?
The cash to sales ratio of Guided Therapeutics (QB) is 107.69
What is the reporting currency for Guided Therapeutics (QB)?
Guided Therapeutics (QB) reports financial results in USD
What is the latest annual turnover for Guided Therapeutics (QB)?
The latest annual turnover of Guided Therapeutics (QB) is USD 98k
What is the latest annual profit for Guided Therapeutics (QB)?
The latest annual profit of Guided Therapeutics (QB) is USD -3.66M
What is the registered address of Guided Therapeutics (QB)?
The registered address for Guided Therapeutics (QB) is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Guided Therapeutics (QB) website address?
The website address for Guided Therapeutics (QB) is www.guidedinc.com
Which industry sector does Guided Therapeutics (QB) operate in?
Guided Therapeutics (QB) operates in the ELECTROMEDICAL APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
IONMAssure Holdings Corporation (CE)
$ 0.0489
(4,889,900.00%)
104
RZONFRize Oncology Inc (PK)
$ 0.16
(39,900.00%)
5k
SBESSouth Beach Spirits Inc (CE)
$ 0.0001
(9,900.00%)
3.54M
ELIQQElectriq Power Holdings Inc (CE)
$ 0.01
(9,900.00%)
100
GEGPGold Entertainment Group Inc (PK)
$ 0.0001
(9,900.00%)
2M
EWGFFEat Well Investment Group Inc (CE)
$ 0.0001
(-99.80%)
2k
FPWMCharlestowne Premium Beverages Inc (PK)
$ 0.000001
(-99.67%)
179
MMMMQuad M Solutions Inc (CE)
$ 0.000001
(-99.50%)
4.17M
TPTWTPT Global Tech Inc (CE)
$ 0.000001
(-99.00%)
3.74M
ASTAAstra Veda Corporation (CE)
$ 0.000001
(-99.00%)
60k
HMBLHUMBL Inc (PK)
$ 0.0003
(50.00%)
467.25M
PSRUValiant Eagle Inc (PK)
$ 0.00015
(50.00%)
295.58M
PSWWPrincipal Solar Inc (PK)
$ 0.000568
(184.00%)
240.14M
TONRTonner One World Holdings Inc (PK)
$ 0.0002
(0.00%)
179.89M
AFFUAffluence Corp (PK)
$ 0.00025
(25.00%)
176.35M

GTHP Discussion

View Posts
GetSeriousOK GetSeriousOK 7 days ago
Regarding 1800 Diagonal Lending.....

GTHP also borrowed money from them last year, but that wasn't convertible and I believe those have been paid (or will be by the maturity date of May 30, 2025).

1800 Diagonal Lending has a history of immediately dumping shares they acquired through note conversion. The SEC just instigated proceedings against Mark Cramer, sole owner of 1800 Diagonal Lending and two other LLC's he uses to lend money, for dumping converted shares so fast that he's acting like a securities dealer. The SEC calls him a "two-time recidivist violator."
https://www.sec.gov/files/litigation/complaints/2024/comp25995.pdf

GTHP's two new loans mature on January 30th, 2026 and February 28, 2026. It's important not to default on these loans because the loans aren't convertible unless GTHP defaults.

By 2026, there's a decent chance the PMA could be approved. I wish I could say there's a decent chance SMI will pay $$$ millions by 2026 but I can't say that with a straight face. I can't even say the NMPA will approve the Luviva scan this year. SMI just keeps lying about paying their bills so who knows how much of their NMPA story we can believe. I believe that doctors in China completed the Chinese clinical trial and the results were great, but those doctors didn't submit an application to the NMPA -- SMI did.
👍️0
GetSeriousOK GetSeriousOK 1 week ago
The most important part of the 10-Q: US Clinical trials. As of May 1, 2025, approximately 360 patients have been enrolled and tested, which represents approximately ninety percent of the 400 anticipated patients needed to complete the study. When they field their 10-K they said "To date, approximately 320 patients have been enrolled and tested." If "To Date" meant March 31st, they completed 40 patients between March 31st and May 1st, which is faster than expected, since they have been moving at a rate of about 50 per quarter.

I wish they had said "As of [mm/dd/yyyy]" instead of "To date" in the 10-K, but I'm expecting the US clinical trials to finish by the end of Q2 or shortly thereafter. That will be a welcome PR!

I don't think it will take GTHP much time to file the amended PMA after the clinical trials finish because GTHP has had nothing else to do but prepare, and I don't think the FDA will take much time to approve the PMA because it's not a new PMA -- it's an amendment to a PMA that was first submitted in 2010. Of course, in the world of developmental biotech, nothing happens as fast as expected.
👍️0
GetSeriousOK GetSeriousOK 1 week ago
10-Q out, No revenues booked in Q1.

Deferred Revenue reduced by $179,000 because the company took $180,000 of SMI money and applied it to reimbursement of expenses the Company incurred in prior periods.

They borrowed money from an entity called "Diagonal Lending LLC" and it's convertible if GTHP defaults. It's important to note that the notes aren't convertible UNLESS GTHP defaults. Have to keep an eye on this SEC case against Diagonal Lending et al:

https://www.sec.gov/files/litigation/complaints/2024/comp25995.pdf

No real news on SMI or the NMPA. To nobody's surprise, SMI failed to pay again, and they signed another Extension Agreement. We're all waiting to see what the NMPA does of course.
👍️0
GetSeriousOK GetSeriousOK 1 week ago
Really wondering what happened to JoJo and his other aliases. His latest alias lasted for just one post.

I'm bored so I read the 10-K a little more carefully, and this surprised me -- might be a typo? Our Chinese partner, SMI, filed the application with NMPA for approval of LuViva as a Class 3 medical device in China on October 16, 2024. I thought SMI filed for a Class 2 device. Class 2 and 3 in China are not the same as Class 2 and Class 3 in the USA.

oh well, NMPA decision very likely in Q2 so let's gird our loins. Meanwhile, here's some Safe Harbor hype from the 10-K: In Europe, our distribution partners, Newmars Medical Technologies (“Newmars”), is actively pursuing potential customers in Poland, Hungary and Romania, where we have obtained the required approvals to sell our products though Newmars. In addition, an application for approval has been filed in Russia, although current geopolitics presents uncertainty as to the ability to sell and market new medical technology in that country.

In Turkey, we have been in contact with three different medical groups representing over 60 individual hospitals and clinics. We have entered contract discussions for supplying LuViva to the Turkish Ministry of Health and also with a medical device distributor located in Ankara.

In Indonesia, our contracted distributors are in discussions with the local government hospital system of Sulawesi, one of the nation’s most populous islands. During the fourth quarter of 2024, we received an order and full payment for four devices from Indonesia. We expect additional orders for 22 – 26 devices in 2025.
👍️0
splintered sunlight splintered sunlight 1 month ago
Thanks

Appreciate the through response.
👍️0
splintered sunlight splintered sunlight 1 month ago
Thanks
👍️0
GetSeriousOK GetSeriousOK 1 month ago
Just another Form 4. Insider acquiring more shares -- direct purchase to fund the company and get more warrants, and a conversion of debt into stock.

So --

* good, in that insiders continue to fund the company without a return to toxic lenders.

* indifferent, in that it's only $15k new money now.

* indifferent, in that an 8-K about SMI paying money would have been better. (Tongue in cheek)

on a different note: OTC tickers like GTHP aren't directly falling because of the tariff crash, but they are indirectly getting hurt because shareholders are selling bits and pieces of all their holdings, presumably to pay for margin calls in their fund/ETF accounts. Examples: in GTHP, somebody put a large block up for sale at .08, and in RDGL, somebody put up a large block at 10-11 cents. It's not because something is wrong with GTHP or RDGL -- it's because something is REALLY wrong elsewhere.

Personally, I don't use margin and I'm not old enough to have RMD's, so this tariff crash isn't affecting me. It's a buying opportunity, if anything.

I'm half expecting to hear from Jojo again. He was a big buyer last year at .09. I guess he doesn't want to bash when the PPS is .09 or lower.


GTHP
👍️0
splintered sunlight splintered sunlight 1 month ago
Filing out today.

Good, bad, or indifferent???
👍️0
GetSeriousOK GetSeriousOK 2 months ago
10-K out. As of 12/31/2024 they had $849,000 in deferred revenue, some of which must be SMI and some of which must be that order they sold in Q4 but didn't book by EOY (because there's not much revenue booked in 2024).

SMI is up to their old tricks, which should surprise NOBODY. SMI has paid $855,144 so far total, but they missed their payments again in 2024, forcing yet ANOTHER update to the AMI Agreement (see pages F-29 and F-30): To meet demand for the remainder of 2024 and for the first half of 2025, SMI agreed to purchase a minimum of 500,000 RFID chips, at prices ranging between $1.00 and $1.40 per chip. To meet demand for the second half of 2025, SMI agreed to purchase an additional 100 IPs and 1,000,000 RFID chips, at prices ranging between $1.00 and $1.40 per chip. SMI agreed to pay a minimum of $400,000 to the Company prior to December 31, 2024, to cover additional components, devices and costs incurred by the Company. On January 3, 2025, after confirming with SMI that no payment was forthcoming, the Company notified SMI in writing that the failure to make this payment constituted a breach of the October 21, 2024 Agreement. A second non-monetary breach also was identified in the Company’s correspondence to SMI. SMI informed the Company that it intended to cure the monetary breach and the Company agreed to negotiate a partial settlement by April 1, 2025.

If by April 30, 2025, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. So maybe we'll see a PR tomorrow about a payment from SMI? hahahaha just kidding. Of interest here, though, is that Guided seems to be preparing to kick SMI to the curb, finally, because of that line about "commercialization by April 30."

NMPA approval by April 30? We'll see. Commercialization by April 30? Not a chance. However, this is new: On January 6, 2025, SMI informed us that NMPA found the application complete and was commencing their review. The most important catalyst: US Clinical trials. My prediction ten days ago was "I expect them to say 'over 300 enrolled' in the annual report." Here's the synopsis of the most recent PMA Amendment: We held a follow up teleconference with FDA on January 28, 2020 and filed a pre-submission document to the Agency on February 17, 2020 that summarized the clinical protocol to be submitted for FDA review. In the second quarter of 2021, we reached basic agreement with the FDA on a study protocol that would require approximately 400 women to be tested. During 2022, FDA asked for a few additional clarifications which we resolved, allowing for the study to begin in 2023. To date, approximately 320 patients have been enrolled and tested. In summary: No surprises, good or bad, other than MAYBE the company is ready to show SMI the door.

We're still under the radar. Let's watch for NMPA news in April.
👍️0
GetSeriousOK GetSeriousOK 2 months ago
My US Trials timeline prediction looks correct.

They updated the clinicaltrials.gov site today. Estimated completion of trial: July 31, 2025. Since the protocol states that the outcome measures happen "up to 60 days after completion of enrollment," that means they expect to complete enrollment in May 2025. I expect them to say "over 300 enrolled" in the annual report.

The company probably won't know about the Chinese NMPA decision when they file the 10-K.... too soon, IMO, unless there were issues.


.
👍️0
GetSeriousOK GetSeriousOK 2 months ago
There's no reverse split on the horizon. The O/S is only 66 million and they won't be uplisting to NASDAQ any time soon and the death spiral financing is long gone, so there's no reason whatsoever to do a R/S.

Here's what's on the horizon:

* Finish US clinical trials.
* Submit a PMA addendum to the FDA.
* NMPA (Chinese FDA) decision.

10-K due at the end of the month. They sold a little product in Q4 but probably not enough to matter (we'll see how much). We'll also see if SMI paid any money -- unlikely, IMO, but if the NMPA approves the device, Guided can find a way to kick SMI to the curb and capitalize -- SMI has served their purpose. Even if the NMPA doesn't approve, that Chinese clinical trial makes the PMA addendum as close to a slam dunk as you can get with the FDA.

Officers (insiders) own 25% of the O/S. Auctus and GPB Holdings own another 25%. That leaves only 33 million in the hands of investors like us. Nothing is guaranteed, but if/when this thing runs, that low float could make it run pretty hard. I like the odds.



GTHP
👍️0
Zeppo Zeppo 2 months ago
....from 50 cents to a dime over the past few years. It looks like, yet, another reverse split is on the horizon .......even with so little stock remaining.
👍️0
GetSeriousOK GetSeriousOK 3 months ago
Timeline musings.......

I think they will reach the US 400-patient goal in Q2.

The last count was 255 patients at the end of Q3. They were moving along at about 50 patients a quarter. They did about 80 between Q1 and Q2 last year but it really looks like about 50 per quarter. I expect them to say "over 300" in the annual report.

Chinese NMPA approval timeline: about six months if no problems. They submitted in Oct 2024.

The annual financial statement in four weeks will be interesting because we'll see if they got any money from SMI in Q4. I still don't think SMI has any money to GIVE, but there would be no point of completing the clinical trials in China and submitting to the NMPA if they didn't have some sort of a plan. Wouldn't an SMI payment be a nice surprise. Won't matter much in terms of PPS, IMO, because this ticker is still under the radar and will stay there until the FDA play later in 2025, but without SMI money they'll probably have to dilute again before the EOY.




't
👍 1
GetSeriousOK GetSeriousOK 3 months ago
Welcome to iHub!

myjo and myjog are the same person. He or she used those two aliases to create fake conversations about GTHP, against iHub rules. That kind of attempted manipulation is a criminal act.

Also, that person instigated the cyber bullying and cyber harassing between us. Yes, I took up the gauntlet, and I will again if someone tries bullying and harassing me.

Like, for example, if myjo/myjog comes back with a new alias and picks up where he or she left off.

Would you like to talk about GTHP instead of criticizing me with your very first post? Share your DD with us!

The next financial statement will be a 10-K, not a 10-Q. The last couple of 10-Q's and the recent Form 4's explain pretty well "what's happening here." Also, the clinical trial page on clinicaltrials.gov -- that hasn't been updated for year, so it's due.
👍 1
alanbloomfield1981 alanbloomfield1981 3 months ago
What’s happening here?
When’s management publishing latest 10-Q?
GetSeriousOK, you want to take side of management then it’s ok. However stop cyber bullying & cyber harassing of management’s critics. You don’t have any rights to do that.
I hope myjo or myjog, whosoever he or she is, he or she is okay.
👍️0
Franken-vestor Franken-vestor 3 months ago
Thanks for that update - I appreciate it. I'll try to stay on my traxone for the drunkeness an my Bacardi for Myjob.
👍️0
GetSeriousOK GetSeriousOK 3 months ago
Welcome back!

Here's what you missed:

To everyone's surprise, SMI got a 400-patient multi-location clinical trial in China COMPLETED and submitted an application to the Chinese FDA. SMI is now supposed to pay Guided $$$ millions but we all know SMI has no money so...... whatever. Still great news IMO because Guided can use include that Chinese clinical trial when they submit to the US FDA which I think will happen in 2025, although.... read next bullet.

Guided finally started their US clinical trials while you were gone, and that might be ending.... well who knows. The last time they updated progress in October, they said "over half [of 400] enrolled," which means over 200, which means.... mid 2025? Here's the clinicaltrials.gov website that I check every now and then to see if the paint has dried. It predicted the trials would end in December 2024 but we all knew that wasn't going to happen. Trials rarely end as scheduled, especially when it's 400 participants.

https://clinicaltrials.gov/study/NCT04915495?tab=results

And they sold some devices and disposables to Indonesia in December, so the financials will have something other than crickets to report at the end of March, even if SMI still hasn't paid them those pie-in-the-sky $$$ millions.

Lots of Form 4's in the past two years. The top three insiders own a lot of stock.

Finally, our resident basher is still at work, although he hasn't been seen since flaming out pretty hard in mid December 2024 . Not sure why he abruptly stopped, but rest assured, he'll be back.


Cheers!
👍️0
Franken-vestor Franken-vestor 3 months ago
So I was drunk for 2 years. Big deal.
👍️0
Franken-vestor Franken-vestor 4 months ago
Is this thing still on? I've been wondering why my light bill has been so high for 2 years.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
Look up the definition of HYPERBOLE. It's a useful tool when used sparingly, but when you use it in almost every sentence, it's farce.

Your post here is word salad that makes no logical sense. You're demanding that Guided does something that cannot be done.

The problem is, you're making libelous statements. I think Guided Management is going to sue you for libel in 2025, and if they do, it's a slam-dunk case. The only question is whether or not they think you're worth the effort. I guess we'll find out soon. Meanwhile, enjoy the rest of 2024!
👍️0
myjog myjog 5 months ago
I thought you said using words like NEVER is hyperbole? Who’s hyperbole & hypocrite now?
Don’t worry about my health. I’m well capable of taking care of my own health. And if you are so much worried about my health then have a call with full-of-shit GTHP management & ask them to ensure SMI pays them in full by December-end ‘24.
If a deadbeat defaults on a loan, how is that the bank's fault? You are right if the deadbeat defaults on a loan that’s not bank’s fault but then wise & intelligent & clever banks never give an another loan again to the deadbeat defaulter. Whereas here SMI defaulted not only once but many times & yet the non-performing, no-capability, lazy management keeps on giving them chances after chances & partnering with a defaulter & non-trustworthy partner. That’s fraudulent behavior. They say fool me once shame on you but fool me twice shame on me. SMI made a complete fool out of GTHP management not only once but many times. What are GTHP management’s vested interests in keep on partnering with a payment defaulted & non-trustworthy entity? Did SMI pay bribes to GTHP management? Due to their non-performance, no-capability & laziness stockholders suffered 99% losses.
They say where there’s a will there’s a way. If lazy GTHP management would have at least tried to find another trustworthy & paying partner then may be they would have found one. But it appears that the lazy management never tried that search option.
If GTHP management can’t find a way to ensure SMI pays 1.34ML$ by year end ‘24, then they are not worthy of their jobs. To find a way is their job & if they can’t do that then they don’t deserve their jobs. Why they need a common stockholder to inform them how to do their jobs & a way about how to make their partner pay? Don’t they know how to do their jobs? If hey know then they must find a way to ensure SMI pays them in full by December-end ‘24.
For the last time don’t bother to reply to my any posts on any forum ever again anywhere.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
Guided could NEVER have found anyone else to do all that work for free. SMI was a godsend, regardless of whether they pay Guided any money or not.

57,000 shares is not a selloff.

When I say that you're full of shit, notice that I'm not calling you an idiot or "intellectually challenged" or dim-witted or stupid. It's just an observation that your hyperbole-laden posts are lies and that anyone who uses two aliases to create a fake conversation and/or buys the stock while bashing is full of shit.

You are getting very angry and I'm worried about your health. Please go pet a dog or give a dollar to a homeless person and try to let that anger go. Celebrate life. You shouldn't care that I see through you. You still managed to buy a fair amount of this stock under a dime in the past year, didn't you? So congratulations!
👍️0
myjog myjog 5 months ago
For an intellectually challenged individual like you no wonder I’ve to repeat myself. So here we go again. I don’t get angry ever & I certainly don’t get angry at idiots, stupids & dim-witted. I pity their intelligence (if they have any). Next time before you call me names like full of shit, take a look in the mirror & may be a realization of a “light bulb” moment.
If you are so bullish on the stock why do t you buy at ask price? You don’t buy because you are full of shit & a paid pumper.
When the 1st time SMI didn’t obey their contractual payment obligations, at that time itself GTHP management should have started to search for another paying, trustworthy partner. However lazy & no-capacity GTHP management didn’t do that. Now SMI fully know that GTHP is stuck with them & SMI is exploiting the undue disadvantage of GTHP’s situation to their fullest to their own selfish advantage.
I suspect that SMI has already informed GTHP about that they can’t pay 1.34ML$ by this year end & somehow that insider information was leaked to the market today & hence the sell off today.
Stockholders lost 99% of value in stock solely because of non-performing, no-capability, lazy management.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
I own a lot of GTHP stock. Probably not as much as YOU, considering how you've been steadily buying while bashing, but I own a lot.

GTHP management owns a lot of GTHP stock too.

Please explain why is SMI's inability to pay the fault of GTHP management? If a deadbeat defaults on a loan, how is that the bank's fault?

How do you propose GTHP management "[ensures] SMI pays them 1.34ML$ in full by December 31st 2024?" Travel to China and threaten to break their thumbs?

Do you think Shenghuo would have ever completed a 400-patient clinical trial in China and submitted an application to the NMPA?

Do you think GTHP management could have found anyone ELSE to do all that for free?

How can you expect anyone to not think you're full of shit when you're so full of shit?

LOL I'm sorry, it's wrong for me to pick on you like this. It's making you angry and that's not in the Holiday Spirit. I'm interfering with your bashing and buying, aren't I? I'll stop. Happy Holidays!
👍️0
myjog myjog 5 months ago
If you are so bullish on the stock & company, where are your buys? Put your money where your mouth is.
We shall soon see if GTHP management has what it takes to ensure SMI pays them 1.34ML$ in full by December 31st 2024.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
Do you deny using two aliases to create a fake conversation bashing this stock? Aliases myjo and myjog?

And do you deny buying the stock while you were bashing? Even though you admitted that you and your associates were buying while you were bashing?

I can show you those posts if you want to see them again.

Don't you agree that someone who used two aliases to fake a conversation is full of shit?

And don't you agree that someone who is buying a stock while bashing it is full of shit?
👍️0
GetSeriousOK GetSeriousOK 5 months ago
You say "Data doesn't lie." Look at the historical data for daily volume for the past YEAR and note the days that had 100,000 volume or more:

* none in November
* three days in October
* none in September or August
* one day each in July, June, May, April....
* two days in March....
* three days in February....
* and none in January.

There were more days that had ZERO volume than days that had 100,000 volume. Typical daily volume is under 10,000 shares -- under $2000 per day. That's the data and it doesn't lie. Your FUD doom-and-gloom about selling and dumping and "massive volume" is proven false by the data you claim to trust.

But don't let me stop you from taking your own advice and shorting this stock. We'll watch your progress on REGSHO.

And have you looked up the definition of "hyperbole" yet? Words like ever, never, always, absolutely.... When someone uses hyperbole as much as you, it loses its effect. It makes you sound childish. You might want to dial it back.
👍️0
myjog myjog 5 months ago
I don’t get angry ever & I certainly don’t get angry at idiots, stupids & dim-witted. I pity their intelligence (if they have any). Next time before you call me names like full of shit, take a look in the mirror & may be a realization of a “light bulb” moment.
Data doesn’t lie.
I’m bearish right from the beginning get-go because of poor-performing & no-capacity management have a great product at hand & they are literally ruining the stock. In last 8-+ years, management made stockholders 99% of losses & still management enriched themselves by awarding dividend & all kind of stock payments at the expense of stockholders’ losses.
We shall see if management has what it takes to make SMI pay them 1.34ML$ at then end of this year. Just 14 more days remaining. Clock is ticking. Tick-tock-tick-tock.
Looking at today’s trading my “guess” is that SMI is not paying them a dime & that insider news was leaked to market.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
That's your advice? "short it?"

Short a penny stock trading at 16 cents?

BTW when I said there was no volume the volume was 2000 shares. Did you buy 55,000 shares just to prove me wrong? LOL it'll take more than 55,000 shares to create volume here. The next catalyst will be either a big payment from SMI or the completion of the USA clinical trials. Until then, there's not going to be any volume, unless Auctus or some other big holder decides to dump.

You seem angry. That's a shame. It's the holiday season! Cheer up. Maybe bring back your second alias and create another fake conversation so you have someone other than me to talk to!
👍️0
myjog myjog 5 months ago
Paid pumpers are saying there’s no volume. The fact & truth & data says that there are almost 55K net sells at any salvage price anyone can get. Who’s full of shit now? Data doesn’t lie. Paid pumpers are full of shit. Bid is at 0.155$ & there are neither any buyers nor any buying support. Where are paid pumpers’ buys? They are full of shit, lies & bs. This is going down. Short it.
👍️0
myjog myjog 5 months ago
It’s a sell, sell, sell. Sell at any salvage price you can get. Short this. This is going down the toilet. Paid pumpers are full of shit. They are not buying. If any one have any courage to buy, then show your buys. Otherwise you are full of shit. Show your buys!
👍️0
GetSeriousOK GetSeriousOK 5 months ago
Level 2 shows that you're full of shit.

There's no "unlimited supply of GTHP stock" and the MM's aren't doing anything illegal. There's simply no volume here and there won't be until there's a significant catalyst.

The entire time you've been bashing, you've been buying, or trying to buy anyway. Where do your Bids currently sit? And do you think you can drive the PPS down to your price by bashing every day?
👍️0
myjog myjog 5 months ago
No matter how many buys are done at an ask price of 0.175$, it appears that broker-dealers / market-makers have an unlimited supply of GTHP stock to be sold at 0.175$ price. Bid stubbornly sits at 0.17$ & never goes up! What a mess this stock has become!
👍️0
myjog myjog 5 months ago
That’s your opinion .
Keep your BS opinions to yourself.
If you have value add information about GTHP then post here. Otherwise don’t ever bother to reply to any of my posts on any forum anywhere ever.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
Stop posting bullshit and FUD about GTHP and nobody will ever respond to you again.

Keep posting bullshit and FUD about GTHP and you'll have to put up with people calling you out.
👍️0
myjog myjog 5 months ago
If any of those 2 things don’t happen then never ever bother to reply to any of my posts ever again on any forum anywhere.
Whether or not SMI will pay GTHP 1.34ML$ by 12/31/2024 is going to be known in next 15 days anyway.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
LOL just remember your promise, Elmer FUD. If SMI pays the $1.4 million and the clinical trial completes in Q1, you'll "not only go away but will go away with praising post of GTHP management on this forum."

I hope you're shorting GTHP. I really do.
👍️0
myjog myjog 5 months ago
GTHP stockholders,
GTHP management’s paid pumpers are trying to portray a rosy picture. However keep in mind that in spite of SMI proven to be defaulted on multiple times about their contractual payment obligations, GTHP management is not able to do anything about it GTHP management keeps on continuing with payments defaulted & non-trustworthy partner. From this you can get the picture about who’s in driver’s seat.
it’s a known fact now that they are not able to complete the US clinical trial by 2024-end. They missed the deadline again. What’s new? From this you can the picture that clearly GTHP management is not in driver’s seat.
Because of this abysmally poor performance stock is stuck at 0.17$. There’s neither any buying support for the stock nor any trading happening in the stock nor it’s going up at all. Because of this the broker-dealers / market-makers are able to manipulate the trading & price in this stock. Because of this stockholders suffered losses.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
paid pumpers, LOL

GTHP bashing manipulator-wannabees appear to not know or ignore the fact that SMI has missed deadlines a dozen times, not just three -- but who cares?

Nobody ever thought SMI would pay a red cent. To my surprise, they paid hundreds of thousands $$$ and they completed a 400-patient clinical trial at mutiple hospitals that succeeded -- and then SMI submitted an application to the NMPA.

You have to stretch pretty far to paint all that as Fear Uncertainty and Doubt. Yet you still try to spread FUD.

And why? You stopped buying -- your 9-cent bids are long buried. So why keep bashing?

"What are GTHP Management’s vested interests in continuing with a payment defaulter & non-trustworthy partner?" you can't be serious. Guided is in the driver's seat. If SMI doesn't pay, all their work was for naught because they can't sell the Luviva Scan without Guided's help and permission. If the Luviva Scan gets Chinese approval and SMI disappears, HOW is that a negative? Guided got Chinese clearance for free and they can easily find another reseller.

You make no sense, but you forge ahead with your FUD. It's bizarre.
👍️0
myjog myjog 5 months ago
GTHP management’s paid pumpers appear to not know or ignore the fact that SMI didn’t adhere to contractual obligations not only once not only twice but three times now. They say fool me once shame on you but fool me twice shame on me. SMI made a complete fool out of GTHP management not only once not only twice but three times now. SMI don’t have money to pay to GTHP is not GTHP’s fault. However fully knowing that SMI don’t have money & yet GTHP management still continue to partner with a payment defaulted & non-trustworthy partner is definitely GTHP management’s fault. When SMI didn’t pay GTHP the 1st time at that time itself if GTHP management would have started the efforts to find another paying & trustworthy partner in China then may be (& I’m just saying my be) things would have been different today. What are GTHP Management’s vested interests in continuing with a payment defaulter & non-trustworthy partner? Why would stockholders suffer losses because of GTHP Management’s poor-performance, laziness, poor-judgement in continuing with a payment defaulted & non-trustworthy partner?
Paid pumpers are so stupid that they don’t understand the difference between bs & value-add post! Alas! Pitying their non-intellect.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
Let GTHP management ensure that SMI pays them 1.34 ML$ in full on or before 31st December 2024 & let GTHP management commit to completing US clinical trials by 1-Q 2025, then I’ll not only go away but will go away with praising post of GTHP management on this forum.LOL you know that SMI doesn't have $1.34 million and that's not Guided management's fault.

The clinical trial will likely finish in Q1 but we know that if by some fluke SMI pays the money you won't go away and you'll never praise GTHP management, so why even say it?

If you don't want people to reply to your posts, stop posting bullshit. Is that so hard to do?

SMI completed a huge trial and submitted an application to the Chinese FDA without any cost to Guided. Why are you so negative about that? We've all known for YEARS that SMI had no money to pay Guided so the contractual $$$ numbers never meant anything. I frankly don't know how they managed to get that trial done and submit that application. SMI made glass tubes before they found GTHP.
👍️0
myjog myjog 5 months ago
GTHP management’s paid pumpers are so full of shit that in spite of me telling them 100s of times not to bother replying to my posts, they are so stupid & dim-witted that fail to understand plain simple English.
They don’t have any value-add comments or contributions for this forum so they go tho the lowest level of personal attacks.
Let GTHP management ensure that SMI pays them 1.34 ML$ in full on or before 31st December 2024 & let GTHP management commit to completing US clinical trials by 1-Q 2025, then I’ll not only go away but will go away with praising post of GTHP management on this forum.
Is GTHP management up for this challenge?
👍️0
GetSeriousOK GetSeriousOK 5 months ago
If SMI doesn't pay up by 12/31/2024 will you go away?

That's the logical conclusion from all your hyperbole.

"absolutely"
"at all"
"the only way"
"absolutely"
"no exceptions"
"Period"

Really, if SMI doesn't pay by 12/312024 and you're still here in January, that proves you're full of shit. As if further proof was needed.

Happy Holidays.
👍️0
myjog myjog 5 months ago
In spite of the somewhat Ok news, there’s absolutely no trading in this stock. This will inform stockholders about how market doesn’t trust this company’s management at all. This company’s management missed their deadlines so many times before & their performance is so abysmally low that right now market doesn’t trust them for a good news as well.
Right now the only way to recover from this horrible & horrendous situation & regain trust from market is for this company’s management to absolutely ensure that by December-end 2024 SMI pays them 1.34 ML$ “in full”. No exceptions. Period.
👍️0
myjog myjog 5 months ago
The PPS have a potential to reach 1$ (4$) & may go there if & only if this company’s management builds on the December momentum & absolutely ensures that
1) SMI pays them 1.34 ML$ as per their contractual obligations by December-end ‘24
2) Don’t do any RS or fund raising diluting existing stockholders’ equity.
As I said, it’s now all in the hands of this company’s management & let’s hope they don’t screw it up this golden opportunity this time around.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
The minimum to UPLIST from OTC to NASDAQ is $4 PPS

The $1 PPS rule is for STAYING on NASDAQ.

But forget that. The big takeaway from your post here is: after all your bashing and FUD, you think the PPS is going to $1 and that's without any regard for the US clinical trial.

No wonder you've been buying the whole time you've been bashing. You must be done buying now?
👍️0
myjog myjog 5 months ago
Although “displaying exemplary performance” & “meeting deadlines” & “bringing value to stockholders instead of enriching management at the expense of shareholders’ losses”, terms like these are foreign territory & uncharted waters for this company’s management. That’s the way to get stock price at a respectable level of at least 1$ & then uplist to NASDAQ.

The 2nd despicable, outright disgusting & the most-preferred way of non-performing, zero-to-no capability management is RS (an easy way out for lazy management).

Stockholder of this company hope that management of this company chooses the former instead of the latter.

It appears that December is off to a good start & if they keep the momentum going & absolutely ensure that SMI pays them 1.34 ML$ as per their contractual obligations by December-end ‘24 then this stock will see a 1$ price without RS. It’s now all in the hands of this company’s management & let’s hope they don’t screw it up this golden opportunity this time around.
👍️0
GetSeriousOK GetSeriousOK 5 months ago
Explain how they can uplist to NASDAQ with a PPS of 18 cents.

BTW the money from this sale will be deferred revenue on the 10-K if they're not shipping until 2025 so brace yourself for that.
👍️0
myjog myjog 5 months ago
Something is better than nothing.
4 LuViva & 1200 disposables. Order may be worth 100K$. That’s why there’s neither uptick in trading volume nor uptick in stock price. The broker-dealer / market-maker GTSM so tightly manipulates the trading & the stock price in this stock that nothing not a thing can be done about it. The only way appears forward is to utilise the proceeds from this latest order to uplist to NASDAQ.
👍️0
myjog myjog 6 months ago
It appears that GTSM broker-dealer/market-maker has an unlimited supply of GTHP stock at 0.175$. This broker-dealer/market-maker is 1 of the broker-dealers/market-makers actively involved in stock price manipulation.
👍️0

Your Recent History

Delayed Upgrade Clock